Published 9 hours ago • loading... • Updated 9 hours ago
Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry
The report covers the market for peptide and oligonucleotide therapeutics, called TIDES, through 2030 and how contract manufacturers are expanding capacity.
On Friday, November 20, 2026, Frost & Sullivan and Medtide Inc. jointly released the 2026 Global Peptide and Oligonucleotide Drug Industry White Paper in Shanghai, China.
The white paper examines the global market for peptide and oligonucleotide therapeutics, collectively known as TIDES, and maps manufacturing outlooks through 2030.
Widespread use of GLP-1 therapies for diabetes and obesity has increased peptide demand, while advances in drug delivery are expanding oligonucleotide development into cardiovascular and metabolic conditions.
Global CDMOs are automating individual synthesis steps, introducing continuous purification, and using digital batch records to trace production and strengthen quality data traceability.
Drugmakers increasingly prioritize CDMOs with demonstrated scale-up experience, regulatory submission support, and capacity reservation capabilities to ensure reliable commercial supply across global markets.